EHA Library - The official digital education library of European Hematology Association (EHA)

CLINICAL CHARACTERISTICS OF PATIENTS WITH MYELOID NEOPLASMS FROM REGIONS CONTAMINATED BY DEPLETED URANIUM: 20 YEAR ANALYSIS
Author(s): ,
Amina Kozaric
Affiliations:
Pathology, Cytology and Human Genetics,Clinical Center of the University of Sarajevo,Sarajevo,Bosnia and Herzegovina
,
Lejla Mehinovic
Affiliations:
Pathology, Cytology and Human Genetics,Clinical Center of the University of Sarajevo,Sarajevo,Bosnia and Herzegovina
,
Sabira Kurtovic
Affiliations:
Hematology,Clinical Center of the University of Sarajevo,Sarajevo,Bosnia and Herzegovina
Aida Dizdarevic
Affiliations:
Hematology,Clinical Center of the University of Sarajevo,Sarajevo,Bosnia and Herzegovina
(Abstract release date: 05/19/16) EHA Library. Kurtovic-Kozaric A. 06/09/16; 132777; E1228
Assoc. Prof. Amina Kurtovic-Kozaric
Assoc. Prof. Amina Kurtovic-Kozaric
Contributions
Abstract
Abstract: E1228

Type: Eposter Presentation

Background
Depleted uranium (DU), a radioactive heavy metal, is used in military ammunition. It emits alpha particles and has the half life of 4.5 billion years. Studies have shown the potential health risks of contamination by DU by wounding, ingestion, and inhalation. In vivo and in vitro experiments showed the carcinogenic potential of DU by neoplastic transformation of human and mouse cells, leading to the development of myeloid neoplasms. It is assumed that the DU exposure induces genomic stability leading to carcinogenesis. During the war in Bosnia, DU ammunition was used in several towns, including the town of Hadzici. United Nations have measured the concentrations of depleted uranium and showed a significant increase in the municipality of Hadzici. 

Aims
Increased numbers of patients with blood cancers was observed by hematologists in DU-stricken area, so we systematically analyzed hematological patients from this region in the last 20 years, from 01.01.1996. – 31.12.2015. 

Methods
Two regions were analyzed: DU stricken and a control region. As a control region, patients from a town with the same population number were used. Patient data from 01.01.1996. – 31.12.2015 was collected including age at diagnosis, sex, address, blood parameters, cytogenetics, therapy, and survival. 

Results
In the 20 year analyzed period from 01.01.1996–31.12.2015, we found 717 patients with hematological conditions (437 from DU-stricken town vs. 280 from control town). There were 74 patients with myeloid malignancies (54 vs. 20), 55 patients with non Hodgkin lymphoma (26 vs. 29), 21 patients with Hodgkin lymphoma (9 vs. 12), and 6 patients with ALL (4 vs. 2).  Among the myeloid neoplasms, MDS showed a 6 fold change. The median age at diagnosis for MDS patients was 50 vs. 65. Male to female ratio was MDS 0.5 vs. 1. Median age at diagnosis was 50 in DU-stricken area vs. 65 in control region. Patients from the DU area showed the trends towards higher IPSS-R score (50% of patients had intermediate and 17% had very high score) compared to the control and international data. 

Conclusion
Clinical parameters showed more severe course of myeloid malignancies in DU stricken area compared to the control and internatinal data. Further investigation is needed to elucidate the possible causes of stark increase in myeloid neoplasms in DU stricken area.

Session topic: E-poster

Keyword(s): Clinical outcome, Myeloid malignancies, Radiation
Abstract: E1228

Type: Eposter Presentation

Background
Depleted uranium (DU), a radioactive heavy metal, is used in military ammunition. It emits alpha particles and has the half life of 4.5 billion years. Studies have shown the potential health risks of contamination by DU by wounding, ingestion, and inhalation. In vivo and in vitro experiments showed the carcinogenic potential of DU by neoplastic transformation of human and mouse cells, leading to the development of myeloid neoplasms. It is assumed that the DU exposure induces genomic stability leading to carcinogenesis. During the war in Bosnia, DU ammunition was used in several towns, including the town of Hadzici. United Nations have measured the concentrations of depleted uranium and showed a significant increase in the municipality of Hadzici. 

Aims
Increased numbers of patients with blood cancers was observed by hematologists in DU-stricken area, so we systematically analyzed hematological patients from this region in the last 20 years, from 01.01.1996. – 31.12.2015. 

Methods
Two regions were analyzed: DU stricken and a control region. As a control region, patients from a town with the same population number were used. Patient data from 01.01.1996. – 31.12.2015 was collected including age at diagnosis, sex, address, blood parameters, cytogenetics, therapy, and survival. 

Results
In the 20 year analyzed period from 01.01.1996–31.12.2015, we found 717 patients with hematological conditions (437 from DU-stricken town vs. 280 from control town). There were 74 patients with myeloid malignancies (54 vs. 20), 55 patients with non Hodgkin lymphoma (26 vs. 29), 21 patients with Hodgkin lymphoma (9 vs. 12), and 6 patients with ALL (4 vs. 2).  Among the myeloid neoplasms, MDS showed a 6 fold change. The median age at diagnosis for MDS patients was 50 vs. 65. Male to female ratio was MDS 0.5 vs. 1. Median age at diagnosis was 50 in DU-stricken area vs. 65 in control region. Patients from the DU area showed the trends towards higher IPSS-R score (50% of patients had intermediate and 17% had very high score) compared to the control and international data. 

Conclusion
Clinical parameters showed more severe course of myeloid malignancies in DU stricken area compared to the control and internatinal data. Further investigation is needed to elucidate the possible causes of stark increase in myeloid neoplasms in DU stricken area.

Session topic: E-poster

Keyword(s): Clinical outcome, Myeloid malignancies, Radiation

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies